Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Here, the association of 1,25(OH)2D and PTH(1 to 84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

1,25-Dihydroxyvitamin D to PTH(1 to 84) Ratios Strongly Predict Cardiovascular Death in Heart Failure

Study design awaiting verification · PLoS ONE · 2015

Original publication title

1,25-Dihydroxyvitamin D to PTH(1 to 84) Ratios Strongly Predict Cardiovascular Death in Heart Failure

Damien Gruson; Benjamin Ferracin; Sylvie A. Ahn; Claudia Zierold; Frank Blocki; Douglas M. Hawkins; Fabrizio Bonelli; Michel F. Rousseau

© 2015 Gruson et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

1,25(OH)2D and its ratios to PTH(1 to 84) strongly and independently predict cardiovascular mortality in chronic HF.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Vitamin D deficiency and hyperparathyroidism are common in patients with heart failure (HF). There is a growing body of evidence supporting the role of vitamin D and parathyroid hormone (PTH) in cardiac remodeling and worsening of HF. Lack of reliable automated testing of 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite of vitamin D, has limited its contribution to the prognostic assessment of HF. Here, the association of 1,25(OH)2D and PTH(1 to 84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.

Source: Objectives

Abstract: What methods does the paper describe?

We conducted a single center prospective cohort including 170 chronic HF patients (females n = 36; males n = 134; NYHA II-IV; mean age: 67 years; etiology: ischemic n = 119, dilated cardiomyopathy n = 51; mean LVEF: 23%). The primary outcome was cardiovascular death.

Source: Methods

Abstract: Results

Serum levels of 1,25(OH)2D decreased markedly with increased HF severity. Medians were 33.3 pg/mL for NYHA-II patients, 23.4 pg/mL for NYHA-III, and 14.0 pg/mL for NYHA-IV patients (p<0.001). Most patients had levels of 25(OH)D below 30ng/mL, and stratification by NYHA functional class did not show significant differences (p = 0.249). The 1,25(OH)2D to PTH(1 to 84) ratio and the (1,25(OH)2D)2 to PTH(1 to 84) ratio were found to be the most significantly related to HF severity. After a median follow-up of 4.1 years, 106 out of 170 patients reached the primary endpoint.

Cox proportional hazard modeling revealed 1,25(OH)2D and the 1,25(OH)2D to PTH(1 to 84) ratios to be strongly predictive of outcomes.

Source: Results

Abstract: Conclusions

1,25(OH)2D and its ratios to PTH(1 to 84) strongly and independently predict cardiovascular mortality in chronic HF.

Source: Conclusions
Authors’ abstract

Objectives

Vitamin D deficiency and hyperparathyroidism are common in patients with heart failure (HF). There is a growing body of evidence supporting the role of vitamin D and parathyroid hormone (PTH) in cardiac remodeling and worsening of HF. Lack of reliable automated testing of 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite of vitamin D, has limited its contribution to the prognostic assessment of HF. Here, the association of 1,25(OH)2D and PTH(1 to 84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.

Methods

We conducted a single center prospective cohort including 170 chronic HF patients (females n = 36; males n = 134; NYHA II-IV; mean age: 67 years; etiology: ischemic n = 119, dilated cardiomyopathy n = 51; mean LVEF: 23%). The primary outcome was cardiovascular death.

Results

Serum levels of 1,25(OH)2D decreased markedly with increased HF severity. Medians were 33.3 pg/mL for NYHA-II patients, 23.4 pg/mL for NYHA-III, and 14.0 pg/mL for NYHA-IV patients (p<0.001). Most patients had levels of 25(OH)D below 30ng/mL, and stratification by NYHA functional class did not show significant differences (p = 0.249). The 1,25(OH)2D to PTH(1 to 84) ratio and the (1,25(OH)2D)2 to PTH(1 to 84) ratio were found to be the most significantly related to HF severity. After a median follow-up of 4.1 years, 106 out of 170 patients reached the primary endpoint.

Cox proportional hazard modeling revealed 1,25(OH)2D and the 1,25(OH)2D to PTH(1 to 84) ratios to be strongly predictive of outcomes.

Conclusions

1,25(OH)2D and its ratios to PTH(1 to 84) strongly and independently predict cardiovascular mortality in chronic HF.

Publication and source details

Original title: 1,25-Dihydroxyvitamin D to PTH(1 to 84) Ratios Strongly Predict Cardiovascular Death in Heart Failure

Damien Gruson; Benjamin Ferracin; Sylvie A. Ahn; Claudia Zierold; Frank Blocki; Douglas M. Hawkins; Fabrizio Bonelli; Michel F. Rousseau

PLoS ONE · 2015

Competing Interests: Claudia Zierold, Frank Blocki, and Fabrizio Bonelli are employees of DiaSorin Inc., a provider of in vitro diagnostic products. For the current study, their contribution was to provide advice for the best use and monitoring of novel assays and scientific input for results interpretation as well as editing of manuscript. The authors are also working on a provisional patent. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Conceived and designed the experiments: DG DH F. Bonelli CZ F. Blocki MR. Performed the experiments: DG BF SA DH MR. Analyzed the data: DG SA DH F. Bonelli CZ F. Blocki MR. Contributed reagents/materials/analysis tools: DG BF SA DH F. Bonelli CZ F. Blocki MR. Wrote the paper: DG SA DH F. Bonelli CZ F. Blocki MR.

* E-mail: damien.gruson@uclouvain.be
© 2015 Gruson et al2015Gruson et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.DiaSorin Inc., funder, provided support in the form of salaries for authors Claudia Zierold, Frank Blocki, and Fabrizio Bonelli, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:31:27.362805+00:00

DOI: 10.1371/journal.pone.0135427 · PMC4550259